saxagliptin
Onglyza	Pharmaceutical company: Bristol-Myers Squibb www.onglyza.com

Pharmacologic classification: dipeptidyl peptidase-4 enzyme inhibitor
Therapeutic classification: antidiabetic drug
Pregnancy risk category: B

AVAILABLE FORMS
Tablets: 2.5, 5 mg

INDICATIONS AND DOSAGES
Adjunct to diet and exercise to improve glycemic control in type 2 diabetes—
Adults: 2.5 to 5 mg P.O. once daily.

CONTRAINDICATIONS AND CAUTIONS
Use cautiously in patients taking secretagogues, such as sulfonylureas, because of increased risk of hypoglycemia.

INTERACTIONS
Drug-drug. Strong CYP3A4/5 inhibitors (ketoconazole, atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin): May increase saxagliptin levels. Reduce dose to 2.5 mg P.O. daily.

ADVERSE REACTIONS
CNS: headache, peripheral edema.
EENT: sinusitis.
GI: abdominal pain, gastroenteritis, vomiting.
GU: UTI.
Metabolic: hypoglycemia.
Respiratory: upper respiratory tract infection.
Skin: urticaria.
Other: facial edema.

Reactions may be common, uncommon, life-threatening, or COMMON AND LIFE-THREATENING.

Home - Guest Registry - Customer Service

Brought to you by Lippincott Williams & Wilkins,
publisher of Lippincott's Nursing Drug Guide.
For help on how you should use this site, see our Disclaimer.

© Copyright 2010 by Lippincott Williams & Wilkins